Fulgent Genetics Soars 16.41% on Q2 Earnings Surge

Fulgent Genetics' stock surged 16.41% in pre-market trading on August 1, 2025, driven by strong financial performance in the second quarter.

Fulgent Genetics reported robust financial results for the second quarter of 2025, with total revenue reaching $81.8 million. Core revenue, a key metric for the company, grew by 16% year-over-year to $81.7 million. This strong performance led the company to raise its full-year 2025 core revenue guidance to $320 million, surpassing analyst expectations.

The company's operational efficiency also improved, with a year-over-year increase in gross margin from 37% to 42% for the three months ended June 30, 2025. This improvement was driven by increased revenue and cost management strategies.

Fulgent Genetics' strong Q2 earnings and positive outlook for the remainder of the year have bolstered investor confidence, contributing to the significant pre-market stock price increase.